ReviewFrontiers in aging neuroscience2014
Involvement of dopamine loss in extrastriatal basal ganglia nuclei in the pathophysiology of Parkinson's disease.
Review in Frontiers in aging neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Cognitive trajectories in Parkinson's disease patients, a review on the impact of subthalamic deep brain stimulation (STN-DBS) and emerging adaptive strategies.Translational psychiatry · 2026Review
- Diagnostic Potential of Macromolecular Proton Fraction Mapping Combined with Quantitative Susceptibility Mapping as a Subcortical Biomarker for Parkinson's Disease.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026Article
- Tremor pathophysiology.Clinical parkinsonism & related disorders · 2026Review
- The Role of ΔFosB in the Pathogenesis of Levodopa-Induced Dyskinesia: Mechanisms and Therapeutic Strategies.Molecular neurobiology · 2025Review
- Efficacy of Virtual Reality-Based Interventions on Cognitive Function in Patients With Neuropsychiatric Disorders: Systematic Review and Meta-Analysis of Randomized Controlled Trials.JMIR serious games · 2025Review
- Molecular and Behavioral Neuroprotective Effects of Clavulanic Acid and Crocin in Haloperidol-Induced Tardive Dyskinesia in Rats.Molecular neurobiology · 2025Article
- Knowledge, attitude, and practice of healthcare professionals toward cognitive dysfunction in Parkinson's disease and cognitive rehabilitation.BMC medical education · 2024Article
- Lipid-based nanoparticles for drug delivery in Parkinson's disease.Translational neuroscience · 2024Review
- Safety and Effectiveness of Rasagiline in Chinese Patients with Parkinson's Disease: A Prospective, Multicenter, Non-interventional Post-marketing Study.Drug safety · 2023Article
- Susceptibility to geometrical visual illusions in Parkinson's disorder.Frontiers in psychology · 2023Article
- Repositioning of drugs for Parkinson's disease and pharmaceutical nanotechnology tools for their optimization.Journal of nanobiotechnology · 2022Review
- Glycation modulates glutamatergic signaling and exacerbates Parkinson's disease-like phenotypes.NPJ Parkinson's disease · 2022Article
- Sex is a defining feature of neuroimaging phenotypes in major brain disorders.Human brain mapping · 2022Review
- Intrapallidal injection of cannabidiol or a selective GPR55 antagonist decreases motor asymmetry and improves fine motor skills in hemiparkinsonian rats.Frontiers in pharmacology · 2022Article
- Pharmacological and Non-pharmacological Treatments of Sleep Disorders in Parkinson's Disease.Current neuropharmacology · 2021Review
- The relationships of vitamin D, vitamin D receptor gene polymorphisms, and vitamin D supplementation with Parkinson's disease.Translational neurodegeneration · 2020Review
- Detection of a High-Turnover Serotonin Circuit in the Mouse Brain Using Mass Spectrometry Imaging.iScience · 2019Article
- HIV-1 Tat regulation of dopamine transmission and microglial reactivity is brain region specific.Glia · 2018Article
- Non-human primate models of PD to test novel therapies.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a neurological disorder characterized by the manifestation of motor symptoms, such as akinesia, muscle rigidity and tremor at rest. These symptoms are classically attributed to the degeneration of dopamine neurons in the pars compacta of substantia nigra (SNc), which results in a marked dopamine depletion in the striatum. It is well established that dopamine neurons in the SNc innervate not only the striatum, which is the main target, but also other basal ganglia nuclei including the two segments of globus pallidus and the subthalamic nucleus (STN). The role of dopamine and its depletion in the striatum is well known, however, the role of dopamine depletion in the pallidal complex and the STN in the genesis of their abnormal neuronal activity and in parkinsonian motor deficits is still not clearly determined. Based on recent experimental data from animal models of Parkinson's disease in rodents and non-human primates and also from parkinsonian patients, this review summarizes current knowledge on the role of dopamine in the modulation of basal ganglia neuronal activity and also the role of dopamine depletion in these nuclei in the pathophysiology of Parkinson's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.